Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Rockwell Medical, Inc. RMTI

Healthcare  —  Drug Manufacturers Specialty & Generic
8.37 (0.20) (2.33%) as of 25 Sep
Market cap
$34.5M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Rockwell Medical, Inc. (RMTI) Business Profile

Updated before January 2025

Company Overview

Rockwell Medical, Inc. (RMTI) is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of treatments for end-stage renal disease (ESRD) and chronic kidney disease (CKD). Founded in 1995 and headquartered in Wixom, Michigan, Rockwell Medical has established itself as a leader in the renal health sector. The company’s mission is to improve the quality of life for patients suffering from kidney-related conditions by providing innovative therapies and solutions.

Rockwell Medical’s leadership team is composed of experienced professionals with deep expertise in the healthcare and pharmaceutical industries. The company’s CEO, Mark Strobeck, Ph.D., brings a wealth of experience in biopharmaceuticals and strategic growth. Under his leadership, Rockwell Medical has focused on expanding its product portfolio and strengthening its position in the global market.

Core Business Segments

Rockwell Medical operates primarily in the renal health sector, offering a range of products and services designed to address the needs of patients with ESRD and CKD. The company’s core business segments include:

1. Dialysis Solutions

Rockwell Medical is a leading provider of hemodialysis concentrates and solutions, which are essential for dialysis treatment. These products include:

  • CitraPure®: A citric acid-based concentrate used in hemodialysis to help maintain proper electrolyte balance.
  • Dry Acid Concentrates: A cost-effective and efficient solution for dialysis providers.
  • Liquid Acid Concentrates: Ready-to-use solutions for dialysis centers.

2. Therapeutic Products

Rockwell Medical has developed innovative therapeutic products to address iron deficiency in dialysis patients. Key products include:

  • Triferic®: A proprietary iron replacement therapy designed to treat iron deficiency anemia in patients undergoing hemodialysis. Triferic is available in two formulations:
    • Triferic Dialysate: Delivered via dialysate during dialysis treatment.
    • Triferic AVNU: An intravenous formulation for broader patient applicability.

3. International Licensing and Partnerships

Rockwell Medical has established partnerships with international distributors to expand the reach of its products. These collaborations enable the company to serve patients in global markets, including Europe, Asia, and South America.

Business Model

Rockwell Medical’s business model is centered on the integration of innovative products and services to address the unmet needs of patients with kidney diseases. The company generates revenue through:

  • Product Sales: Revenue from the sale of hemodialysis concentrates, solutions, and therapeutic products like Triferic.
  • Licensing Agreements: Income from international licensing deals and partnerships.
  • Research and Development: Investment in R&D to develop new therapies and improve existing products.

The company’s vertically integrated approach allows it to control the manufacturing and distribution of its products, ensuring high quality and cost efficiency.

Strategic Direction

Rockwell Medical is focused on achieving sustainable growth through innovation, market expansion, and operational excellence. Key strategic initiatives include:

  • Expansion of Triferic: Increasing the adoption of Triferic in domestic and international markets.
  • Geographic Growth: Expanding its presence in emerging markets with high demand for dialysis products.
  • Product Innovation: Developing new therapies to address unmet medical needs in the renal health sector.
  • Sustainability Goals: Implementing environmentally friendly practices in manufacturing and distribution.

Competitive Landscape

Rockwell Medical operates in a competitive market, facing challenges from both established players and emerging companies. Key competitors include:

  • Fresenius Medical Care: A global leader in dialysis products and services.
  • DaVita Inc.: A major provider of dialysis services in the United States.
  • Amgen Inc.: A biotechnology company offering treatments for anemia in CKD patients.
  • Akebia Therapeutics: A biopharmaceutical company focused on kidney disease therapies.

Despite the competition, Rockwell Medical differentiates itself through its innovative products, such as Triferic, and its focus on patient-centric solutions.

Risk Factors

Rockwell Medical faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: Reliance on a limited number of products, such as Triferic, for revenue generation.
  • Regulatory Challenges: Compliance with stringent regulatory requirements in different markets.
  • Supply Chain Disruptions: Potential disruptions in the supply of raw materials and manufacturing processes.
  • Competition: Intense competition from larger, well-established companies.
  • Financial Constraints: Limited financial resources for R&D and market expansion.

Recent Developments

Rockwell Medical has made significant strides in recent years, including:

  • Launch of Triferic AVNU: The intravenous formulation of Triferic has expanded the company’s product portfolio and addressed a broader patient population.
  • International Partnerships: New licensing agreements with distributors in Asia and Europe to increase global market penetration.
  • Operational Improvements: Streamlining manufacturing processes to enhance efficiency and reduce costs.
  • COVID-19 Impact: Adjusting operations to ensure the uninterrupted supply of dialysis products during the pandemic.

Investment Considerations

Investors considering Rockwell Medical should weigh the following strengths and risks:

Strengths

  • Innovative product portfolio, including Triferic.
  • Strong focus on the renal health sector.
  • Established partnerships for global market expansion.
  • Experienced leadership team.

Risks

  • Dependence on a limited number of products for revenue.
  • Intense competition in the dialysis and renal health markets.
  • Financial challenges related to R&D and market expansion.
  • Regulatory and compliance risks.

Conclusion

Rockwell Medical, Inc. is a key player in the renal health sector, offering innovative products and solutions for patients with ESRD and CKD. With a strong focus on product innovation, market expansion, and operational excellence, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with market dependence, competition, and financial constraints. Overall, Rockwell Medical’s commitment to improving patient outcomes and its strategic initiatives make it a promising company in the biopharmaceutical industry.